Escolar Documentos
Profissional Documentos
Cultura Documentos
ABSTRACT : Developed originally as an antimalarial agent, hydroxychloroquine sulfate (HCQS) is often used
as a slow-acting drug in treating disorders of connective tissue. Over the past two decades, several data have
been accumulated on the systemic effects of HCQS, expanding the potential uses of this drug in different
therapeutic classes. The purpose of this article was to conduct a narrative review with qualitative approach on
clinical, pharmacokinetic and technological aspects of HCQS, aiming to gather relevant pieces of information
for the development of new therapeutic approaches to this drug. A search of the literature of scientific
experimental and theoretical studies in the period 1980-2013 was performed. According to the data collected,
among the activities HCQS, there are the indications for the treatment of autoimmune diseases such as lupus
erythematosus and rheumatoid arthritis. Reports also indicate that HCQS improves insulin sensitivity, ability to
reduce thromboembolic events, reduction of lipid levels and treatment for infection by human immunodeficiency
virus. The evidence found out ocular and cutaneous adverse effects and the formation of three chiral active
metabolites, what encourages studies to evaluate the kinetic behavior of HCQS and the intrinsic
physicochemical characteristics of the drug, which is yet poorly described in the literature.
INTRODUCTION
Initially developed as an antimalarial agent, hydroxychloroquine sulfate (HCQS) - chemically 2-({4[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino)ethan-1-ol - is often used as slow-acting antirheumatic drug
in the treatment of disorders of connective tissue [1-3]. As antimalarial, hydroxychloroquine (HCQ) is
significantly effective against the erythrocytic form of the etiological agents of malaria: Plasmodium
vivax and Plasmodium malariae, and most of Plasmodium falciparum strains. However, recently some
resistance has been observed to chloroquine-resistant Plasmodium falciparum, as well as cases of
resistance against Plasmodium vivax strains. And, despite being used a long time ago in this type of therapy, it is
not known its exact mechanism of action [4-5].
The HCQ has been used also as a secondary drug in the treatment of a variety of chronic diseases. So,
they are administered in conjunction with other agents, resulting in clinical efficacy of diseases such as
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), discoid lupus (LD), sarcoidosis, Sjgren's
syndrome (SS) and photosensitivity diseases [5].The treatment of autoimmune diseases with anti-malarial have
been common for over half a century. Many long-term studies show better results in terms of organ damage and
overall survival of patients receiving these drugs. Over the past two decades, more data have been accumulated
on the systemic effects of HCQS, expanding the potential uses of this medication in different therapeutic classes
[1].The purpose of this article was to conduct a narrative review with qualitative feature on clinical,
pharmacokinetic and technological aspects of HCQS, aiming to gather relevant information for development of
new therapeutic approaches to this drug.
53
II.
CLINICAL ASPECTS
The HCQS brings benefits to long term in the treatment of SLE and RA and has become a standard
component of therapy for patients with these diseases. Table 1 provides a systematic overview of the
effectiveness of treatment with HCQS on clinical manifestations of major diseases where the use of the drug is
recommended.
Table 1. Systematic review of evidence of efficacy of HCQS in the treatment of RA and SLE [1].
Illness
Evaluation of efficacy
Type of evidence
Reference
RA
Systematic literature;
[6]
[7]
[8]
Articular index;
Seizure frequency;
Organ failure;
Survival;
[9]
[10-11]
[12-13]
[14]
Cutaneous manifestations;
[15]
[13]
[16]
[17]
Glomerulonephritis;
Complete renal remission for
membranous nephropathy.
Reports demonstrated the efficacy of HCQ in different conditions from those which have rheumatic
diseases. Some of these reports are described below [1].The first information relates to diabetes mellitus.
Hypoglycemic conditions in patients treated with HCQ and CQ has being observed. Three small clinical studies,
randomized and controlled, using patients without other rheumatic complications and receiving a relatively high
dose of HCQS (600 mg) reinforced this situation [18].A brief prospective study with obese, non-diabetic and
non-carriers of autoimmune diseases demonstrated an improvement of insulin sensitivity after six weeks of
treatment with HCQ. These results suggest that there is not only a reduction in the incidence of type two
54
55
III.
PHARMACOKINETIC ASPECTS
The HCQS is marketed and administered to patients as racemate, equimolar mixture of two
enantiomers: (+)-HCQ and (-)-HCQ. However, no information is available about the possibility of
stereoselective disposition and pharmacological activities of the isolated enantiomers [2]; [62].Despite this fact,
56
IV.
TECHNOLOGICAL ASPECTS
Preformulation studies can be defined as the full investigation of the physico-chemical properties of the
active, alone or combined with other excipients that make up a pharmaceutical ingredient formulation. Perhaps,
it is the limiting step of product development and requires special attention throughout the industry involved in
this process. Therefore, it is necessary to apply the philosophy of quality by design, once it must plan, eliminate
or diminish interference and expenditure of resources [75].Therefore, when choosing a drug molecule to
develop new, safe and effective therapeutic alternatives,
it is important to gather information regarding the intrinsic characteristics of the molecule.Regarding
HCQS, Semeniuk and coworkers (2008) [4] demonstrated by techniques of crystallography and X-ray
diffraction, the crystal structure projection and intermolecular interactions of the monocrystal drug. According
to the study, each of the nitrogen atoms of the free base is a proton donor in intermolecular hydrogen bonds with
57
Figure 1. Structures of HCQ, its impurities and degradation products (adapted from Saini and Bansal, 2013[83]).
58
59
V.
CONCLUSION
Despite the classical indication as an antimalarial drug, HCQS is presenting a diversity of clinical
evidence that awaken the search for a better understanding of their biological properties. Among the activities
reported in the literature, there are indications for the treatment of autoimmune diseases such as lupus and RA,
where the drug is already an established alternative therapy. Reports also reveal the effectiveness of HCQS in
different diseases from those present in rheumatic conditions, such as improved insulin sensitivity, ability to
reduce thromboembolic events, reduction of lipid levels and treatment of infection by HIV.
60
REFERENCES
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
[24]
[25]
N.J. Olsen, M.A. Schleich and D.R. Karp, Multifaceted effects of hydroxychloroquine in human disease, Semin Arthritis Rheum.,
43(2), 2013, 264-72.
A.J. McLachlan, S.E. Tett, D.J. Cutler and R.O. Day, Disposition of the enantiomers of hydroxychloroquine in patients with
rheumatoid arthritis following multiple doses of the racemate, Br J Clin Pharmacol., 36(1), 1993, 78-81.
S.E. Tett, D.J. Cutler, R.O. Day and K.F. Brown. Bioavailability of hydroxychloroquine tablets in healthy volunteers, Br J Clin
Pharmacol., 27(6), 1989, 771-79.
A. Semeniuk, A. Niedospial, J. Kalinowska-Tluscik, W. Nitek and B. J. Oleksyn, Molecular geometry of antimalarial amodiaquine in
different crystalline environments, J Mol Struct., 875(13), 2008, 3241.
T.A. Shapiro and D.D. Goldberg, Quimioterapia das infeces por protozorios, In: L.S. Goodman; A. Gilman, As Bases
Farmacolgicas da Teraputica, (Rio de Janeiro: McGraw-Hill; 2006) 927-9.
C. Gaujoux-Viala, J.S. Smolen, R. Landew, M. Dougados, T.K. Kvien, E.M. Mola, M. Scholte-Voshaar, P. Van Riel and L. Gossec,
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic
literature review informing the EULAR recommendations for the management of rheumatoid arthritis, Ann Rheum Dis., 69(6), 2010,
1004-9.
K. Pavelka, K.P. Sen, Z. Pelskov, J. Vcha and K. Trnavsk, Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis:
a double blind comparison of two dose regimens, Ann Rheum Dis, 48(7), 1989, 542546.
I.H. Nuver-Zwart, P.L. van Riel, L.B. van de Putte and F.W. Gribnau. A double-blind comparative study of sulphasalazin and
hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazin. Ann Rheum Dis, 48, 1989, 389-395.
The Canadian Hydroxychloroquine Study Group, A Randomized Study of the Effect of Withdrawing Hydroxychloroquine Sulfate in
Systemic Lupus Erythematosus, N Engl J Med, 324, 1991, 150-154.
N. Costedoat-Chalumeau, G. Leroux, J.C. Piette and Z. Amoura, Why all systemic lupus erythematosus patients should be given
hydroxychloroquine treatment?, Joint Bone Spine, 77(1), 2010, 4-5.
B.J. Fessler, G.S. Alarcn, G. Jr. McGwin, J. Roseman, H.M. Bastian, A.W. Friedman, B.A .Baethge, L. Vil and J.D. Reveille.
Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage
accrual, Arthritis Rheum., 52(5), 2005, 1473-80.
G. Ruiz-Irastorza, M. Ramos-Casals, P. Brito-Zeron and M.A. Khamashta, Clinical efcacy and side effects of antimalarials in
systemic lupus erythematosus: a systematic review, Ann Rheum Dis, 69(1), 2010, 208.
S.K. Shinjo et al., Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin
American inception cohort, Arthritis Rheum, 62, 2010, 855862.
J.A. James et al., Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus, Lupus, 16,
2007, 401409.
C. Francs, A. Cosnes, P. Duhaut, N. Zahr, B. Soutou, S. Ingen-Housz-Oro, D. Bessis, J. Chevrant-Breton, N. Cordel, D. Lipsker and
N. Costedoat-Chalumeau, Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus:
a French multicenter prospective study, Arch Dermatol, 148(4), 2012, 47984.
G.J. Pons-Estel, G.S. Alarco, G. McGwin, M.I. Danila and J. Zhang, H.M. Bastian, et al., Protective effect of hydroxychloroquine on
renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort, Arthritis Rheum., 61(6), 2009, 8309.
N. Kasitanon, L.S. Magder and M. Petri, Predictors of survival in systemic lupus erythematosus, Medicine (Baltimore), 85(3), 2006,
147-56.
A. Quatraro, G. Consoli, M. Magno, F. Caretta, A. Nardozza, A. Ceriello and D. Giugliano, Hydroxychloroquine in decompensated,
treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug?. Ann Intern Med., 112(9), 1990, 678-81.
E. Mercer, L. Rekedal, R. Garg, B. Lu, EM. Massarotti and D.H. Solomon, Hydroxychloroquine improves insulin sensitivity in obese
non-diabetic individuals, Arthritis Res Ther., 14(3), 2012, 135.
R. Johnson and J. Charnley, Hydroxychloroquine in prophylaxis of pulmonary embolism following hip arthroplasty, Clin Orthop
Relat Res., 144, 1979, 1747.
R. Kaiser, C.M. Cleveland and L.A. Criswell, Risk and protective factors for thrombosis in systemic lupus erythematosus: results
from a large, multiethnic cohort, Ann Rheum Dis., 68(2), 2009, 23841.
D.J. Wallace, Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum., 30(12),
1987, 14356.
E. Ernst, M. Rose and R. Lee, Modication of transoperative changes in blood uidity by hydroxychloroquine: a possible explanation
for the drugs antithrombotic effect, Pharmatherapeutica, 4(1), 1984, 4852.
E. Johansson, K. Forsberg and H. Johnsson, Clinical and experimental evaluation of the thromboprophylactic effect of
hydroxychloroquine sulfate after total hip replacement, Haemostasis, 10(2), 1981, 8996.
C. Prowse, D. Pepper and J. Dawes, Prevention of the platelet alpha-granule release reaction by membrane-active drugs, Thromb
Res., 25(3), 1982, 21927.
61
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
[57]
[58]
[59]
M. Petri, C. Lakatta, L. Magder and D. Goldman, Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors
in systemic lupus erythematosus: a longitudinal data analysis, Am J Med., 96(3), 1994, 2549.
P. Rahman, D.D. Gladman, M.B. Urowitz, K. Yuen, D. Hallett and I.N. Bruce, The cholesterol lowering effect of antimalarial drugs
is enhanced in patients with lupus taking corticosteroid drugs, J Rheumatol, 26(2), 1999, 32530.
E. Cairoli, M. Rebella, N. Danese, V. Garra and E. Borba, Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in
systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect, Lupus, 21(11), 2012, 117882.
S.J. Morris, M.C. Wasko, J.L. Antohe, J.A. Sartorius, H.L. Kirchner, S. Dancea, et al., Hydroxychloroquine use associated with
improvement in lipid proles in rheumatoid arthritis patients, Arthritis Care Res (Hoboken), 63(4), 2011, 5304.
H. Mirjafari, A. Al-Husain and I.N. Bruce, Cardiovascular risk factors in inammatory arthritis, Curr Opin Lipidol, 22(4), 2011, 296
301.
J.R. ODell, K.W. Blakely, J.A. Mallek, P.J. Eckhoff, R.D. Leff, S.J. Wees, et al., Treatment of early seropositive rheumatoid
arthritis: a two-year, double-blind comparison of minocycline and hydroxychloroquine, Arthritis Rheum., 44(10), 2001, 223541.
A. Kavanaugh, B. Adams-Huet, R. Jain, M. Denke and J. McFarlin, Hydroxychloroquine effects on lipoprotein proles (the HELP
trial): a double-blind, randomized, placebo-controlled, pilot study in patients with systemic lupus erythematosus, J Clin Rheumatol.,
3(1), 199738.
R. Munro, E. Morrison, A.G. McDonald, J.A. Hunter, R. Madhok and HA. Capell, Effect of disease modifying agents on the lipid
proles of patients with rheumatoid arthritis, Ann Rheum Dis, 56(6), 1997, 3747.
J.C. Sachet, E.F. Borba, E. Bonfa, C.G. Vinagre, V.M. Silva and R.C. Maranho, Chloroquine increases low-density lipoprotein
removal from plasma in systemic lupus patients, Lupus, 16(4), 2007, 2738.
K. Sperber, M. Louie, T. Kraus, J. Proner, E. Sapira, S. Lin, et al., Hydroxychloroquine treatment of patients with human
immunodeciency virus type 1, Clin Ther., 17(4), 1995, 62236.
K. Sperber, G. Chiang, H. Chen, W. Ross, E. Chusid, M. Gonchar, et al., Comparison of hydroxychloroquine with zidovudine in
asymptomatic patients infected with human immunodeciency virus type 1, Clin Ther., 19(5), 1997, 91323.
N.I. Paton and J. Aboulhab, Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low
viral load: safety, efcacy and resistance prole after 144 weeks. HIV Med, 6(1), 2005, 1320.
L. Aguirre-Cruz, K.J. Torres, H. Jung-Cook, C. Fortuny, E. Sanchez, A. Soda-Mehry, et al., Short communication: preferential
concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects, AIDS Res Hum Retroviruses, 26(3), 2010, 33942.
A. Savarino, L. Gennero, K. Sperber and J.R. Boelaert, The anti-HIV-1 activity of chloroquine, J Clin Virol., 20(3), 2001, 1315.
J.M. Rolain, P. Colson and D. Raoult, Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral
infections in the 21st century, Int J Antimicrob Agents, 30(4), 2007, 297308.
G. Chiang, M. Sassaroli, M. Louie, H. Chen, V.J. Stecher and K. Sperber, Inhibition of HIV-1 replication by hydroxychloroquine:
mechanism of action and comparison with zidovudine, Clin Ther, 18(6), 1996, 108092.
M.F. Marmor, U. Kellner, T.Y. Lai, J.S. Lyons and W.F. Mieler, American Academy of Ophthalmology. Revised recommendations
on screening for chloroquine and hydroxychloroquine retinopathy, Ophthalmology, 118(2), 2011, 415-22.
F. Wolfe and M.F. Marmor, Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and
systemic lupus erythematosus, Arthritis Care Res, 62(6), 2010, 77584.
L. Tanenbaum and D.L. Tuffanelli, Antimalarial agents, Arch. Dermatol, 116, 1980; 587-591.
A. Kuznik, M. Bencina, U. Svajger, M. Jeras, B. Rozman and R. Jerala, Mechanism of endosomal TLR inhibition by antimalarial
drugs and imidazoquinolines, J Immunol, 186(8), 2011, 4794804.
F.D. Goldman, A.L. Gilman, C. Hollenback, R.M. Kato, B.A. Premack and D.J. Rawlings, Hydroxychloroquine inhibits calcium
signals in T cells: a new mechanism to explain its immunomodulatory properties, Blood, 95(11), 2000, 34606.
D.E. Moore and V.J. Hemmens, Photosensitization by anti-malarial drugs, Photochem Photobiol., 36, 1982, 71-77.
D.E. Moore and S.R. Tamat, Photosensitizing by drugs: photolysis of some chlorine-containing drugs, J. Pharm. Pharmacol., 32,
1980, 172-77.
H.H. Tnnesen, A.L. Grislingaas, S.O. Woo and J. Karlsen, Photochemical stability of antimalarials, Int J Phar, 43, 1988, 215-219.
H.E. Hobbs, A. Sorsby and A. Dreedman. Retinopathy following chloroquine therapy, Lancet, 2, 1959, 478-80.
D.V. Weinberg and D.J. DAmico, Retinal toxicity of systemic drugs. In: Albert DM, Jakobiec FA (Ed.), Principles and practice of
ophthalmology: clinical practice, (Philadelphia: W.B. Saunders, 1994) 3284-5.
M. Easterbrook, The ocular safety of hydroxychloroquine, Semin Arthritis Rheum, 23(2 Suppl 1), 1993, 6267.
M.F. Raines, S.K. Bhargava and E.S. Rosen, The blood-retinal barrier in chloroquine retinopathy, Invest Ophthalmol Vis Sci, 30,
1989, 1726-31.
A. Elman, R. Gullberg, E. Nilsson, et al, Chloroquine retinopathy in patients with rheumatoid arthritis, Scand J Rheumatol, 5, 1976,
1616.
H.E. Hobbs, S.P. Eadie and F. Somerville. Ocular lesions after treatment with chloroquine, Br J Ophthalmol, 45(4), 1961, 284-97.
P. Henkind and N.F. Rothfield, Ocular abnormalities in patients treated with synthetic antimalarial drugs, N Engl J Med, 269, 1963,
433-9.
M.F. Marmor, U. Kellner, T.Y. Lai, J.S. Lyons and W.F. Mieler, MD, American Academy of Ophthalmology Revised
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy, Ophthalmol., 118(2), 2011, 415422.
N. Costedoat-Chalumeau, Z. Amoura, D.L. Huong, P. Lechat and JC, Piette Safety of hydroxychloroquine in pregnant patients with
connective tissue diseases. Review of the literature, Autoimmun Rev., 4(2), 2005, 111-5.
P.M. Izmirly, M.Y. Kim, C. Llanos, P.U. Le, M.M. Guerra, A.D. Askanase, J.E. Salmon and J.P. Buyon, Evaluation of the risk of
anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic
lupuserythematosus exposed to hydroxychloroquine, Ann Rheum Dis., 69(10), 2010, 182730.
62
[61]
[62]
[63]
[64]
[65]
[66]
[67]
[68]
[69]
[70]
[71]
[72]
[73]
[74]
[75]
[76]
[77]
[78]
[79]
[80]
[81]
[82]
[83]
[84]
[85]
[86]
[87]
[88]
[89]
[90]
[91]
[92]
[93]
[94]
[95]
P.M. Izmirly, N. Costedoat-Chalumeau, C.N. Pisoni, M.A. Khamashta, M.Y. Kim, A. Saxena, D. Friedman, C. Llanos, J.C. Piette and
J.P. Buyon. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated
cardiac manifestations of neonatal lupus, Circulation, 126(1), 2012; 7682.
R.A. Levy, O uso de drogas anti-reumticas na gravidez, Rev Bras Reumatol, 45(3), 2005, 124-33.
T.W.G. Solomons and C.B. Fryhle. Qumica Orgnica (Rio de Janeiro: LTC, 2005).
D.R. Brocks and R. Mehvar, Stereoselectivity in the Pharmacodynamics and Pharmacokinetics of the Chiral Antimalarial Drugs, Clin
Pharmacokinet, 42(15), 2003, 1359-82.
D.R. Brocks, F.M. Passutto and F. Jamali, Analytical and semi-preparative high-performance liquid chromatographic separation and
assay of hydroxychloroquine enantiomers, J Chromatogr, 581, 1992, 83-92.
J. Ducharme, I.W. Wainer, H.I. Parenteau and J.H. Rodman, Stereoselective distribution of hydroxychloroquine in the rabbit
following single and multiple oral doses of the racemate and the separate enantiomers, Chirality, 6(4), 1994, 337-46.
A.J. McLachlan, S.E. Tett, D.J. Cutler and R.O. Day, Disposition and absorption of hydroxychloroquine enantiomers following a
single dose of the racemate, Chirality, 6(4), 1994, 360-64.
L.L. Gustafsson, B. Nordmark, O. Ericsson and J. Hermansson, The pharmacokinetics of (+)-and ()-chloroquine in patients with
rheumatoid arthritis [abstract], 3rd World Conference of Clinical Pharmacology and Therapeutics. Stockholm, Sweden, 1986.
A. Haberkorn, H.P. Kraft and G. Blaschke, Antimalarial activity of the optical isomers of chloroquine diphosphate, Tropenmed
Parasitol, 30(3), 1979, 308-12.
J.J. Kanski, Oftalmologia Clnica uma Abordagem Sistemtica (Rio de Janeiro: Revinter, 2000).
J. Iredale, H. Fieger and I.W. Wainer, Determination of the stereoisomers of hydroxychloroquine and its metabolites in plasma and
urine following a single oral administration of racemic hydroychloroquine, Semin. Arthritis Rheum., 23(2-1), 1993, 74-81.
N. Costedoat-Chalumeau, Z. Amoura, J.S. Hulot, H.A. Hammoud, G. Aymard, P. Cacoub, et al, Low blood concentration of
hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus, Arthritis
Rheum, 54:32, 2006, 8490.
J. Ducharme, H. Fieger, M.P. Ducharme, S.K. Khalil and I.W. Wainer, Enantioselective disposition of hydroxychloroquine after oral
of the racemate to healthy subjects, Br J Clin Pharmacol, 40(2), 1995, 27-133.
H. Fieger, J. Iredale and I.W. Wainer, Enantioselective determination of hydroxychloroquine and its major metabolites in urine and
the observation of a reversal in the (+)/(-)-hydroxychloroquine ratio, Chirality, 5(2), 1993, 65-70.
K. Marquardt and T.E. Albertson, Treatment of hydroxychloroquine overdose, Am J Emerg Med. 19(5), 2001, 42024.
L.D. Moretto and J. Calixto, Boas prticas de desenvolvimento de produtos (So Paulo: SINDUSFARMA: Sindicato da Indstria de
Produtos Farmacuticos no Estado de So Paulo, 2009).
F.C. Koyama, Caracterizao de putativo receptor serpentino e estudos sobre a implicao do sistema de ubiquitina/proteossomo na
modulao do ciclo celular de Plasmodium falciparum., doctoral diss., Universidade de So Paulo, So Paulo, 2012.
Brasil, Farmacopia Brasileira (Braslia: Agncia Nacional de Vigilncia Sanitria, 2010).
S. Sweetana and M.J. Akers, Solubility principles and practices for parenteral drug dosage form development, PDA J Pharm Sci
Technol, 50(5), 1996, 330-42.
University of Alberta. In: drugbank version 3.0. 2013. Avaiable at: < http://www.drugbank.ca/>. Access in: 29 out 2014.
British pharmacopoeia (London: HM stationary office, 2008).
The United States Pharmacopoeia - National Formulary (Rockville: The United States Pharmacopeial Convention, 2010).
V.G. Dongre, P.D. Ghugare, P. Karmuse, D. Singh, A. Jadhav and A. Kumar. Identification and characterization of process related
impurities in chloroquine and hydroxychloroquine by LC/IT/MS, LC/TOF/MS and NMR, J Pharm Biomed Anal., 49(4), 2009, 873-9.
B. Saini and G. Bansal, Characterization of four new photodegradation products of hydroxychloroquine through LC-PDA, ESI-MSn
and LC-MS-TOF studies, J Pharm Biomed Anal, 84, 2013, 224-31.
J. Caldwell. Stereochemical determinants of the nature and consequences of drug metabolism, J chromatogr, 694, 1995, 39-48.
J. Caldwell, Importance of stereospecific bioanalytical monitoring in drug development, J Chromatogr, 719, 1996, 3-13.
C.D. Cardoso, Avaliao da Cromatografia Lquida de Alta Eficincia e Eletroforese Capilar no Estudo in vitro do Metabolismo
Enantiosseletivo da hidroxicloroquina, doctoral diss., Universidade de So Paulo, Ribeiro Preto, 2006.
L.M. Lima, C.A.M. Fraga and E.J. Barreiro, O renascimento de um frmaco: talidomida, Qum Nova, 24(5), 2001, 683-88.
K. Verleysen and P. Sandra, Separation of chiral compounds by capillary electrophoresis, Electrophoresis, 19(16-17), 1998, 2798-33.
K. Fried and I.W. Wainer, Column-switching techniques in the biomedical analysis of stereoisomeric drugs: why, how and when, J
Chromatogr B., 689, 1997, 91-104.
K. Tachibana and A. Ohnishi, Reversed-phase liquid chromatographic separation of talidomida, Qum Nova, 24(5), 2001, 683-88.
L.Z. Wang, R.Y. Ong, T.M. Chin, W.L. Thuya, S.C. Wan, A.L. Wong, S.Y. Chan, P.C. Ho and B.C. Goh, Method development and
validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatographytandem mass spectrometry, J
Pharm Biomed Anal, 61, 2012, 86-92.
W. Lindner, M. Rath, K. Stoschitzky and G. Uray, Improved Enantiospecific RP-HPLC Assays for Propranolol in Plasma and Urine
with Pronethalol as Internal Standard, J Anal Toxicol, 15(6), 1991, 327-331.
P.S. Bonato, V.A.P. Jabor and C.M. Gaitani, Anlise enantiosseletiva de frmacos: contribuies da cromatografia lquida de alta
eficincia e eletroforese capilar, Qum Nova, 28(4), 2005, 683-91.
J. Iredale and I.W. Wainer, Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiralchiral
high-performance liquid chromatography, J Chromatogr, 573(2), 1992, 253-8.
A.J. McLachlan, S.E. Tett and D.J. Cutler, High-performance liquid chromatographic separation of the enantiomers of
hydroxychloroquine and its major metabolites in biological fluids using an alpha 1-acid glycoprotein stationary phase, J Chromatogr,
570(1), 1991, 119127
63
A.K. Singh, E.R.M. Kedor-Hackmann and M.I.R.M. Santoro, Cromatografia lquida com fase quiral aplicada na separao
enantiomrica de frmacos cardiovasculares, Rev Bras Cienc Farm, 42(4), 2006, 553-66.
L.R. Snyder, J.J. Kirkland and J.L. Glajch, Chiral Separation, In: L.R. Snyder, J. J. Kirkland and J.L. Glajch (Ed.), Practical HPLC
method development, 2 (New York: Wiley-Interscience, 1997) 537.
D. Ofori-Adjei, O. Ericsson, B. Lindstrm, J. Hermansson, K. Adjepon-Yamoah and F. Sjqvist, Enantioselective analysis of
chloroquine and desethylchloroquine after oral administration of racemic chloroquine, Ther Drug Monit, 8(4), 1986, 457-61.
E.W. McChesney, Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate, Am J Med., 75(1A), 1983, 11-8.
M.M. Conceio, Estudo da degradao trmica de adoante com aspartame, doctoral diss., Universidade Federal da Paraba, Joo
Pessoa, 2004.
64